Systemic treatment and radiotherapy for patients with non-small cell lung cancer (NSCLC) and HIV infection - A systematic review.

[1]  N. Freedman,et al.  Trends and risk of lung cancer among people living with HIV in the USA: a population-based registry linkage study. , 2022, The lancet. HIV.

[2]  N. Nasr,et al.  Evolving Strategies to Eliminate the CD4 T Cells HIV Viral Reservoir via CAR T Cell Immunotherapy , 2022, Frontiers in Immunology.

[3]  O. Kirk,et al.  Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021 , 2022, HIV medicine.

[4]  A. Samri,et al.  Impact of Anti PD-1 Immunotherapy on HIV Reservoir and Anti-Viral Immune Responses in People Living with HIV and Cancer , 2022, Cells.

[5]  Shengying Qin,et al.  Cytochrome P450 Enzymes and Drug Metabolism in Humans , 2021, International journal of molecular sciences.

[6]  S. Peters,et al.  Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  F. Shebl,et al.  Risks of Opportunistic Infections in People With Human Immunodeficiency Virus With Cancers Treated With Chemotherapy , 2021, Open forum infectious diseases.

[8]  J. Mazières,et al.  Assessment of nivolumab in HIV-Infected patients with advanced non-small cell lung cancer after prior chemotherapy. The IFCT-1602 CHIVA2 phase 2 clinical trial. , 2021, Lung cancer.

[9]  G. Yancopoulos,et al.  Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial , 2021, The Lancet.

[10]  L. Buisseret,et al.  Impact of HIV infection on baseline characteristics and survival of women with breast cancer: a systematic review and meta-analysis. , 2020, AIDS.

[11]  H. Kiem,et al.  CAR T-cell therapy for cancer and HIV through novel approaches to HIV-associated haematological malignancies. , 2020, The Lancet. Haematology.

[12]  R. Pfeiffer,et al.  Deaths attributable to cancer in the United States HIV population during 2001-2015. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  J. Mazières,et al.  First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial , 2020, European Respiratory Journal.

[14]  B. Clotet,et al.  Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection: The Phase 2 DURVAST Study. , 2020, JAMA oncology.

[15]  S. Novello,et al.  Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Shih,et al.  Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[17]  H. Groen,et al.  OA04.02 CheckMate 817: First-Line Nivolumab + Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC , 2019, Journal of Thoracic Oncology.

[18]  C. Katlama,et al.  Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience on behalf of the French CANCERVIH network. , 2019, AIDS.

[19]  M. Sznol,et al.  Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study. , 2019, JAMA oncology.

[20]  Richard D Moore,et al.  Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies. , 2019, The lancet. HIV.

[21]  P. V. Van Schil,et al.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  A. Sabichi,et al.  Nivolumab Treatment for Cancers in the HIV-infected Population , 2018, Journal of immunotherapy.

[23]  A. LaCasce,et al.  Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[24]  R. Domselaar,et al.  Immune Checkpoints as the Immune System Regulators and Potential Biomarkers in HIV-1 Infection , 2018, International journal of molecular sciences.

[25]  D. Costa,et al.  Safety and Efficacy of PD‐1 Inhibitors Among HIV‐Positive Patients With Non–Small Cell Lung Cancer , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  P. Rosenberg,et al.  Projected Cancer Incidence Rates and Burden of Incident Cancer Cases in HIV-Infected Adults in the United States Through 2030 , 2018, Annals of Internal Medicine.

[27]  A. Samri,et al.  Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  D. Shin,et al.  HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers. , 2018, Oral oncology.

[29]  C. Hamard,et al.  Nonsmall cell lung cancer from HIV-infected patients expressed programmed cell death-ligand 1 with marked inflammatory infiltrates , 2017, AIDS.

[30]  M. Zins,et al.  HIV is associated with airway obstruction: a matched controlled study , 2017, AIDS.

[31]  Caroline Schenkel,et al.  Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research HIV Working Group. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Toby C. Cornish,et al.  Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy , 2017, JAMA oncology.

[33]  F. Alongi,et al.  Radiotherapy in patients with HIV: current issues and review of the literature. , 2017, The Lancet. Oncology.

[34]  J. Sterne,et al.  Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies , 2017, The lancet. HIV.

[35]  A. Gemma,et al.  Single-institutional experience of clinicopathological analysis and treatment for lung cancer patients with human immunodeficiency virus infection. , 2017, Molecular and clinical oncology.

[36]  D. Rimland,et al.  Immunological and infectious risk factors for lung cancer in US veterans with HIV: a longitudinal cohort study. , 2017, The lancet. HIV.

[37]  Mary E Reid,et al.  The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[38]  S. Pittaluga,et al.  Programed death-1/programed death-ligand 1 expression in lymph nodes of HIV infected patients: results of a pilot safety study in rhesus macaques using anti–programed death-ligand 1 (Avelumab) , 2016, AIDS.

[39]  M. Antoine,et al.  EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients. , 2016, Lung cancer.

[40]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[41]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[42]  E. Engels,et al.  Elevated Cancer-Specific Mortality Among HIV-Infected Patients in the United States. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Kristian Thorlund,et al.  The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations , 2015, Annals of Internal Medicine.

[44]  Judith A. Long,et al.  Cancer Treatment in Patients With HIV Infection and Non-AIDS-Defining Cancers: A Survey of US Oncologists. , 2015, Journal of oncology practice.

[45]  D. Klein,et al.  Survival among HIV-Infected and HIV-Uninfected Individuals with Common Non–AIDS-Defining Cancers , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[46]  Y. Hosomi,et al.  Lung cancer patients harboring epidermal growth factor receptor mutation among those infected by human immunodeficiency virus , 2014, OncoTargets and therapy.

[47]  R. Talamini,et al.  Lung cancer in HIV positive patients: the GICAT experience. , 2014, European review for medical and pharmacological sciences.

[48]  Y. Hosomi,et al.  Concomitant Chemoradiotherapy and Antiretroviral Therapy for HIV-Infected Patients with Locoregionally Advanced Non-Small Cell Lung Cancer: Benefit and Tolerability of Treatment in 2 Cases , 2013, Oncology Research and Treatment.

[49]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[50]  W. Curran,et al.  Human immunodeficiency virus‐associated lung cancer in the era of highly active antiretroviral therapy , 2012, Cancer.

[51]  Y. Hosomi,et al.  Clinical characteristics of Japanese lung cancer patients with human immunodeficiency virus infection , 2012, International Journal of Clinical Oncology.

[52]  L. Cuzin,et al.  Human Immunodeficiency Virus Infection and Non-small Cell Lung Cancer: Survival and Toxicity of Antineoplastic Chemotherapy in a Cohort Study , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[53]  J. Goedert,et al.  Cancer burden in the HIV-infected population in the United States. , 2011, Journal of the National Cancer Institute.

[54]  J. Goedert,et al.  Pulmonary Infections and Risk of Lung Cancer Among Persons With AIDS , 2010, Journal of acquired immune deficiency syndromes.

[55]  L. Pantanowitz,et al.  Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration. , 2010, Clinical lung cancer.

[56]  Y. Nagata,et al.  Acute adverse effects of radiation therapy on HIV-positive patients in Japan: study of 31 cases at Tokyo Metropolitan Komagome Hospital. , 2010, Journal of radiation research.

[57]  J. Pujol,et al.  Interactions between cytotoxic chemotherapy and antiretroviral treatment in human immunodeficiency virus-infected patients with lung cancer. , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[58]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[59]  B. Milleron,et al.  Effect of highly active antiretroviral therapy on survival of HIV infected patients with non-small-cell lung cancer. , 2009, Lung cancer.

[60]  C. Katlama,et al.  Lung cancer in patients with HIV infection and review of the literature , 2004, Medical oncology.

[61]  T. Powles,et al.  Does HIV adversely influence the outcome in advanced non-small-cell lung cancer in the era of HAART? , 2003, British Journal of Cancer.

[62]  A. Pesce,et al.  [Lung cancer in patients infected with human immunodeficiency virus. Clinical course and therapeutic implications]. , 1998, Presse medicale.